secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K/A
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001193125-23-144952
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek acquired flow cytometry business with $43.1M revenue, $4.4M loss in 2022
------------------------------------------------------------------------------

- Purchase price was $46.5M less $1.6M working capital adjustments and transaction fees.
- Net assets acquired: $44.1M assets, $5.7M liabilities, net $38.4M as of Dec 31, 2022.
- FY2022 revenue: $43.1M (product $32.3M, service $10.8M); direct expenses $47.5M.
- Abbreviated financials exclude corporate overhead, taxes, interest; not a standalone entity.
- Acquired brands include Amnis, CellStream, Guava, Muse; closing occurred Feb 28, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523144952/0001193125-23-144952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523144952/d467217d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-144952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer